1-3 of 3
Gregg Smith, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-135872
Published: 2020
Journal Articles

Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis

Jean-Luc Villeval, PhD, Claudine Moratal, M2, Franck Debeurme, Catherine Lacout, Eric Solary, MD, PhD, William Vainchenker, MD, PhD, Christopher J Burns, PhD, Gregg Smith, PhD
Journal: Blood
Blood (2013) 122 (21): 2851.
https://doi.org/10.1182/blood.V122.21.2851.2851
Published: 2013
Journal Articles

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

Animesh Pardanani, MBBS, PhD, Jason Gotlib, M.D., M.S., Vikas Gupta, MD, FRCP, FRCPath, Andrew W Roberts, MBBS, PhD, Martha Wadleigh, MD, Shireen Sirhan, MD, FRCP, Mark R. Litzow, MD, William J Hogan, MBBCh, Kebede Begna, MD, Gregg Smith, PhD, MBA, Linda M Bavisotto, MD, Mark Kowalski, MD, PhD, Ayalew Tefferi, MD
Journal: Blood
Blood (2011) 118 (21): 3849.
https://doi.org/10.1182/blood.V118.21.3849.3849
Published: 2011